Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature

Author:

Dal Jakob1,Leisner Michelle Z2,Hermansen Kasper3,Farkas Dóra Körmendiné2,Bengtsen Mads1,Kistorp Caroline4,Nielsen Eigil H5,Andersen Marianne6,Feldt-Rasmussen Ulla7,Dekkers Olaf M28,Sørensen Henrik Toft2,Jørgensen Jens Otto Lunde1

Affiliation:

1. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark

2. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

3. Department of Medicine, Sydvestjysk Sygehus, Esbjerg, Denmark

4. Department of Internal Medicine, Copenhagen University Hospital, Herlev, Denmark

5. Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark

6. Department of Endocrinology, Odense University Hospital, Odense, Denmark

7. Department of Endocrinology, National University Hospital Rigshospitalet, Copenhagen, Denmark

8. Department of Clinical Epidemiolgy and Metabolism, Leiden University Medical Centre, Leiden, The Netherlands

Abstract

Abstract Context Acromegaly has been associated with increased risk of cancer morbidity and mortality, but research findings remain conflicting and population-based data are scarce. We therefore examined whether patients with acromegaly are at higher risk of cancer. Design A nationwide cohort study (1978 to 2010) including 529 acromegaly cases was performed. Incident cancer diagnoses and mortality were compared with national rates estimating standardized incidence ratios (SIRs). A meta-analysis of cancer SIRs from 23 studies (including the present one) was performed. Results The cohort study identified 81 cases of cancer after exclusion of cases diagnosed within the first year [SIR 1.1; 95% confidence interval (CI), 0.9 to 1.4]. SIRs were 1.4 (95% CI, 0.7 to 2.6) for colorectal cancer, 1.1 (95% CI, 0.5 to 2.1) for breast cancer, and 1.4 (95% CI, 0.6 to 2.6) for prostate cancer. Whereas overall mortality was elevated in acromegaly (SIR 1.3; 95% CI, 1.1 to 1.6), cancer-specific mortality was not. The meta-analysis yielded an SIR of overall cancer of 1.5 (95% CI, 1.2 to 1.8). SIRs were elevated for colorectal cancer, 2.6 (95% CI, 1.7 to 4.0); thyroid cancer, 9.2 (95% CI, 4.2 to 19.9); breast cancer, 1.6 (1.1 to 2.3); gastric cancer, 2.0 (95% CI, 1.4 to 2.9); and urinary tract cancer, 1.5 (95% CI, 1.0 to 2.3). In general, cancer SIR was higher in single-center studies and in studies with <10 cancer cases. Conclusions Cancer incidence rates were slightly elevated in patients with acromegaly in our study, and this finding was supported by the meta-analysis of 23 studies, although it also suggested the presence of selection bias in some earlier studies.

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference34 articles.

1. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study;Dal;Eur J Endocrinol,2016

2. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis;Renehan;Lancet,2004

3. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications;Renehan;Horm Metab Res,2003

4. Mortality and cancer incidence in acromegaly: a retrospective cohort study;Orme;J Clin Endocrinol Metab,1998

5. The incidence of cancer among acromegaly patients: results from the German acromegaly registry;Petroff;J Clin Endocrinol Metab,2015

Cited by 100 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3